vilazodone

Brand: Viibryd

⚠ BBW Prototype Drug
Drug Class: SPARI (serotonin partial agonist reuptake inhibitor)
Drug Family: antidepressant
Subclass: novel antidepressant
Organ Systems: cns

Mechanism of Action

Combines SSRI activity (SERT blockade) with 5-HT1A partial agonism, similar to buspirone. The partial agonism at 5-HT1A autoreceptors may accelerate the desensitization that underlies antidepressant onset, and 5-HT1A postsynaptic partial agonism may contribute to anxiolytic effects.

SERT (serotonin transporter)5-HT1A receptor (partial agonist)

Indications

  • major depressive disorder

Contraindications

  • concurrent MAOI use

Adverse Effects

Common

  • diarrhea
  • nausea
  • vomiting
  • insomnia
  • dry mouth

Serious

  • serotonin syndrome
  • suicidal ideation
  • abnormal bleeding
  • hyponatremia

Pharmacokinetics (ADME)

Absorption bioavailability ~72% with food (must take with food); food increases Cmax by ~147-160%
Distribution protein binding ~96-99%
Metabolism primarily via CYP3A4 (major) with minor CYP2C19 and CYP2D6 contribution
Excretion fecal (~2% unchanged); renal (~1% unchanged)
Half-life 25 hours
Onset 2-4 weeks for antidepressant effect
Peak 4-5 hours
Duration 24 hours
Protein Binding 96-99%
Vd approximately 1400 L

Drug Interactions

Drug / Agent Mechanism Severity
MAOIs serotonin syndrome contraindicated
strong CYP3A4 inhibitors increases vilazodone exposure by 50%; reduce dose to 20 mg/day major
strong CYP3A4 inducers decreases vilazodone levels; increase dose to 80 mg/day moderate

Nursing Considerations

  1. Vilazodone must be taken with food; administration on an empty stomach reduces bioavailability by 50% and may reduce efficacy.
  2. Dose titration is required: start at 10 mg for 7 days, then 20 mg for 7 days, then target 40 mg daily; this gradual titration minimizes GI side effects.
  3. Diarrhea is the most common adverse effect (28% in trials), occurring predominantly in the first 2 weeks; reassure patients this often resolves.
  4. Unlike SSRIs, sexual dysfunction appears less prevalent with vilazodone, possibly due to 5-HT1A agonism counteracting 5-HT2A-mediated sexual effects.

Clinical Pearls

  • Vilazodone's dual mechanism (SERT + 5-HT1A partial agonism) theoretically combines the antidepressant benefit of SSRIs with the anxiolytic mechanism of buspirone in a single molecule.
  • It requires a starter pack and mandatory food administration, making medication reconciliation and patient education critical to achieving therapeutic drug levels.

Safety Profile

Pregnancy use-with-caution
Lactation use-with-caution
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.